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On June 25–26, 2009 the 5th Workshop on innovative
mouse models was held in the Leiden University
Medical Center, Leiden, The Netherlands. The
primary goal of this two-day workshop has always
been to bring together a diverse group of scientists
interested in advanced genome alteration approaches
in the mouse, including key developers of emerging
technologies as well as researchers who wish to apply
and assess these new approaches. The workshop
encourages an in-depth and unvarnished discussion of
these technologies and novel developments in a very
open and informal way, easy accessible for young
and senior researchers. The organising committee
consisting of Jos Jonkers (NKI, Amsterdam, The
Netherlands), Paul Krimpenfort (NKI, Amsterdam,
The Netherlands), Werner Mu ¨ller (University of
Manchester, UK), Els Robanus Maandag (LUMC,
Leiden, The Netherlands), Hein te Riele (NKI,
Amsterdam, The Netherlands), Marian van Roon
(AMC, Amsterdam, The Netherlands) and Sjef Ver-
beek (LUMC, Leiden, The Netherlands) all, except
for Werner Mu ¨ller, participated in the group of Anton
Berns, NKI, Amsterdam and got acquainted with
transgenic technologies and mouse models in his lab.
From 2003 onwards they decided to bring together all
researchers in these ﬁelds in the characteristic
informal, but outstanding workshops on IMM. The
workshops grew from a European meeting to an
international workshop, bringing together 150–200
scientists (see http://workshop.nki.nl). This year,
during the ﬁrst lustrum, topics included: induced
Pluripotent Stemcells, Sleeping Beauty transposon
mutagenesis, large scale generation of conditional
knockouts, in vivo RNAi and mosaic mouse models.
The topics were covered during the ﬁrst day of the
workshop by excellent and outstanding keynote
speakers, while the second day the same topics were
discussed by young scientists in high quality, short
presentations.
All participants were welcomed in the beautiful
and well equipped Lecture Hall of the Leiden
University Medical Center by the initiator of the
IMM workshops Sjef Verbeek. Sjef had a warm
welcome for all of the participants and expressed his
gratitude to all the sponsors of this workshop:
European Science Foundation (ESF), the Interna-
tional Society for Transgenic Technologies (ISTT),
COST, NWO-ZonMw, LUMC, NKI-AvL and AMC,
who made the workshop possible against the low
registration fee.
The ﬁrst session, 28 years of genetically engi-
neered mice: quo vadis?, was kicked off by Anton
Berns from The Netherlands Cancer Institute. Anton
was the pioneer of genetic modiﬁcation of mice in
The Netherlands and almost all of the organising
committee learned about genetic modiﬁcation and
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the milestones of transgenic technology in simple and
funny cartoons. He showed the evolution of mouse
models by unnatural selection and focussed on the
points that need work:—the way the system works
and the access we should have to transgenic and KO
strains—the lack of phenotyping—the genetic back-
ground of the mice generated (FVB and C57Bl/6)—
the generation of compound mutants which is
currently quite slow and should force us to make
compound ES cells and derive mice directly and to
make more use of somatic gene transfer—implemen-
tation of versatile reporter systems. Berns urged us to
join forces and generate support facilities, sufﬁcient
funding, repositories for ES cells and sperm, stan-
dardization and high throughput sites and ﬁnally all
of us should try to increase acceptance of genetically
modiﬁed organisms. During the discussion Berns got
support for his consortia initiatives but they should be
more interactive with the users and be more diverse,
using more technologies.
The second presentation was by Francis Stewart
(TU Dresden) who explained to us the technique of
recombineering: DNA engineering using recombina-
tion in E. coli, fast, easy, and suitable for complex
alleles and site speciﬁc recombination. Francis
explained in detail the process and the use of ‘other’
coli strains (pSC101), pir? strains to lower the
background, and the importance of testing antibiotics
concentrations. He showed the easiness of recombi-
neering, whichwaslateronintheworkshop conﬁrmed
by several enthusiastic users, and promised us that the
‘‘future is ligation-free’’. Francis also discussed some
modiﬁcations of already existing techniques like the
development of site speciﬁc recombination system
Dre/rox (P1) (Sauer and McDermott 2004). The Dre/
rox is a good partner in recombination with Cre/lox,
the two do not show cross-talk and thus can be used
together. Another modiﬁcation is the Flpo; a codon
optimized formofFlpe, (Raymond andSoriano2007).
StewartisdevelopingaFlpodeletermouse,whichwill
be available soon. As an example of the High
Throughput recombineering pipeline Stewart men-
tioned the making of BAC transgenes and targeting
constructs in 96-well plates by 96-well plate electro-
poration, a process that will only take 3–4 days.
Finally Stewart referred to the website of his company
fordetailedinformationonallthesetechniquesandthe
used materials.
The third lecture from this ﬁrst session was by
Barry Rosen (Wellcome Trust Sanger Institute,
Hinxton) who showed us the EUCOMM and KOMP
pipelines of conditional KO’s and deletion KO’s and
the process of design, construction (Gateway system)
and targeting in C57Bl/6N cells (originally from JM8
cells). In the pipeline they learned that promoterless
constructs work very efﬁciently in targeting, that
promoterdriven cassettes are ﬁne as well, but that the
promoter should be removed after homologous
recombination and that the PGK-DTA negative
selection greatly improves the promoter gene target-
ing efﬁciency from 7 to 42%. During the discussion
Barry had a hard time explaining why it takes so long
for the community to receive targeted ES cells after
applying for them. He promises a more efﬁcient
handling and urges people to keep on applying.
After lunch we did go on with session 2, the ﬁrst
out of three sessions entitled ‘New technologies’. First
was Austin Smith (Wellcome Trust Centre for Stem
Cell Research, Cambridge) who talked about captur-
ing pluripotency. Austin showed that for mouse ES
cells LIF and BMP are dispensable and that only two
factors, called 2i, will keep the pluripotency of ES
cells. Everything else is dispensable. He showed the
response of the embryo to 2i by developing the ES
cells to blastocysts and look at the formation of the
epiblast and hypoblast. It turns out that 2i suppresses
the emergence of the hypoblast and promotes the
formation of the epiblast. 2i grown epiblasts make
high grade chimeras and it was suggested that the
epiblast may have no dependence on hypoblast. 2i/
LIF is able to raise ES cells from all mouse strains, as
an example NOD ES cells were shown. Rat embry-
onic stem cells can also be raised and grown on 2i/
LIF/feeders and give rise to germline offspring, but
they are trickier to grow than the mouse cells. Human
‘‘ES’’ cells cannot be maintained in 2i and are
dependent on erk signalling. The question therefore
remains if the human ‘‘ES’’ cells are true ES cells.
Smith was followed up by Andras Nagy (Mount
Sinai Hospital, Toronto) who combined to new
techniques: the formation of induced pluripotent
stem cells (iPS) and transposon/transposase technol-
ogy. Andras showed that ﬁbroblasts can be repro-
grammed by the combination of c-myc, klf4, oct4 and
sox2 (MKOS) to become iPS cells, which can than be
used as therapeutic cells and disease models. The
high risk of these cells is the remaining presence of
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on all kind of biological processes. Andras showed
the use of transposon based transfection by using the
PiggyBac transposon system. The system is very
efﬁcient and cotransduces the transposase and the
GOI in the genome. The second time the transposase
gets active, it removes the GOI but also alters it in
such a way that reintegration is diminished by 50%
(Wang et al. 2008).
Lars Zender (Helmholtz Centre for Infection
Research, Braunschweig) talked about the integrative
oncogenomic approaches for accelerated cancer gene
discovery in hepatocellular carcinoma. He uses
FAH-/- mice as a model system for liver damage
and liver failure and combines it with the transposon/
transposase technology.
And last but not least for this ﬁrst day Adam
Dupuy (University of Iowa, USA) showed the use of
the SleepingBeauty transposon system in oncogene
activation and tumour suppressor gene inactivation in
models of T-ALL. The big disadvantage of all of the
transposon based systems of course remains the local
hopping.
The day was closed with a well visited poster
presentation,andenoughtimeforinformaldiscussions
and get-to-getters with the keynote speakers. A nice
walk through the sunny centre of Leiden, over the
canal bridges and along the mills brought us to the
Kamerlingh Omnes building were we had dinner in
goodcompany andarelaxedbutinspiringatmosphere.
The second day of the workshop was devoted to
short oral presentations selected from the poster
abstracts. All of these can be found back in the
workshop abstract book. The main focus was on the
transposon systems, the use of rat spermatogonial
stem cells (very nice contribution by Ivics), the
efﬁcient system of targeting to the Hprt locus and the
lentiviral-mediated RNAi silencing. Frustrating was
the report that the lentiviral vectors also undergo gene
silencing after generation 6, just when you managed
to segregate the multiple sites of integration! Person-
ally I was very much impressed by the high quality of
the short presentations and the excellent time man-
agement of the speakers. It made it a very nice second
day. The workshop was closed with a forum discus-
sion, which really made it to a ‘‘WORK’’shop.
Moderator Hein te Riele showed in an elegant way
that there was no forum, but that all the participants
formed the forum and that the technique of the
Leiden lecture hall enabled us to follow the discus-
sion on a big screen. It was a stimulating discussion
on very diverse topics. We discussed the use and
efﬁciency of the big consortia and urged them to be
more interactive with their customers and to really set
up a good system for sharing their outcomes with the
scientiﬁc community. We compared the use of ES
cells and iPS cells and discussed the generation of
compound mice and/or compound ES cells. Should
everybody be willing to do all transgenic technology
by themselves or should we outsource techniques to
the experts? How can we really share animal models
once they are published and how do we get new
techniques and materials in our laboratories? And
ﬁnally, what are the risks of working with genetically
modiﬁed models, how should we make genetic
modiﬁcation acceptable to the public and why did
we announce the workshop as Innovative Models in
the LUMC and left out Mouse? These informal
discussions in an open and respectful atmosphere
kept participants bound to their seats till the closing
and formed the cherries on the workshop cake and
made it a pleasure to organise. All participants,
sponsors, and speakers are thanked for their excellent
contributions. We hope to see you all again on the 6th
IMM workshop.
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